HK1049481B - 結晶形式的n-(4-三氟甲基苯基)-5-甲基異噁唑-4-甲酰胺的製備方法 - Google Patents

結晶形式的n-(4-三氟甲基苯基)-5-甲基異噁唑-4-甲酰胺的製備方法

Info

Publication number: HK1049481B
Authority: HK; Hong Kong
Prior art keywords: methylisoxazole; trifluoromethylphenyl; carboxamide; crystal form; preparing crystal
Prior art date: 1997-08-08

Application number

HK03101247.6A

Other languages

English (en)

Other versions

HK1049481A1 (en

Inventor

H‧法施

U‧赫特曼

U‧維斯坦費爾德

E‧帕魯斯

Original Assignee

薩諾費-阿文蒂斯德國有限公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-08

Filing date

2003-02-19

Publication date

2005-07-08

1997-08-08 Priority claimed from DE19734438A external-priority patent/DE19734438A1/de

1997-12-17 Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de

2003-02-19 Application filed by 薩諾費-阿文蒂斯德國有限公司 filed Critical 薩諾費-阿文蒂斯德國有限公司

2003-05-16 Publication of HK1049481A1 publication Critical patent/HK1049481A1/xx

2005-07-08 Publication of HK1049481B publication Critical patent/HK1049481B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Neurology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

HK03101247.6A 1997-08-08 2003-02-19 結晶形式的n-(4-三氟甲基苯基)-5-甲基異噁唑-4-甲酰胺的製備方法 HK1049481B (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19734438A DE19734438A1 (de)	1997-08-08	1997-08-08	Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de)	1997-12-17	1997-12-17	Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (2)

Publication Number	Publication Date
HK1049481A1 HK1049481A1 (en)	2003-05-16
HK1049481B true HK1049481B (zh)	2005-07-08

Family

ID=26038983

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK99102767A HK1017681A1 (en)	1997-08-08	1999-06-30	Crystal from of n-(4-trifluoromethylphenyl)-5-methylisox
HK03101247.6A HK1049481B (zh)	1997-08-08	2003-02-19	結晶形式的n-(4-三氟甲基苯基)-5-甲基異噁唑-4-甲酰胺的製備方法

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HK99102767A HK1017681A1 (en)	1997-08-08	1999-06-30	Crystal from of n-(4-trifluoromethylphenyl)-5-methylisox

Country Status (28)

Country	Link
US (5)	US6060494A (zh)
EP (2)	EP0903345B1 (zh)
JP (2)	JPH11124372A (zh)
KR (2)	KR100544041B1 (zh)
CN (2)	CN1089759C (zh)
AR (1)	AR015418A1 (zh)
AT (2)	ATE207065T1 (zh)
AU (1)	AU752764B2 (zh)
BR (1)	BR9806568A (zh)
CA (1)	CA2245267C (zh)
CZ (3)	CZ292943B6 (zh)
DE (2)	DE59801792D1 (zh)
DK (2)	DK0903345T3 (zh)
ES (2)	ES2166205T3 (zh)
GR (1)	GR3034814T3 (zh)
HK (2)	HK1017681A1 (zh)
HU (2)	HU229232B1 (zh)
ID (1)	ID20667A (zh)
IL (1)	IL125671A (zh)
NO (1)	NO310871B1 (zh)
NZ (1)	NZ331270A (zh)
PL (1)	PL192126B1 (zh)
PT (2)	PT903345E (zh)
RU (1)	RU2224753C2 (zh)
SK (2)	SK285216B6 (zh)
TR (2)	TR200600582A1 (zh)
TW (1)	TW593288B (zh)
UA (1)	UA54411C2 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0903345B1 (de) *	1997-08-08	2000-10-04	Aventis Pharma Deutschland GmbH	Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
DE19908527C2 (de)	1999-02-26	2001-08-30	Aventis Pharma Gmbh	Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
AU779931B2 (en) *	1999-12-16	2005-02-17	Teva Pharmaceutical Industries Ltd.	Novel processes for making- and a new crystalline form of- leflunomide
ES2237553T3 (es) *	2000-02-15	2005-08-01	Teva Pharmaceutical Industries Ltd.	Procedimiento para la sintesis de leflunomida.
WO2002040458A1 (fr) *	2000-11-17	2002-05-23	Takeda Chemical Industries, Ltd.	Derives d'isoxazole
GB0123571D0 (en)	2001-04-05	2001-11-21	Aventis Pharm Prod Inc	Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en)	2001-09-14	2008-09-30	Shionogi & Co., Ltd.	Utilities of amide compounds
WO2003068239A1 (fr) *	2002-02-12	2003-08-21	Sumitomo Pharmaceuticals Co., Ltd.	Nouveaux medicaments d'usage externe
US20050158371A1 (en) *	2002-02-12	2005-07-21	Sumitomo Pharmaceuticals Co., Ltd.	Novel external agent
ES2232332T3 (es) *	2003-03-12	2007-08-16	Teva Pharmaceutical Industries Ltd	Composiciones farmaceuticas estables de desloratadina.
US20060135547A1 (en) *	2003-03-12	2006-06-22	Toth Zoltan G	Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
JP4223428B2 (ja) *	2004-03-31	2009-02-12	富士通メディアデバイス株式会社	フィルタおよびその製造方法
WO2007067710A1 (en) *	2005-12-08	2007-06-14	Amphora Discovery Corporation	Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) *	2006-09-15	2010-09-08	欣凯医药化工中间体（上海）有限公司	N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
UY31695A (es) *	2008-03-10	2009-11-10	Takeda Pharmaceutical	Cristal de compuestos de bencimidazol
CN104666238B (zh)	2009-09-18	2018-04-06	赛诺菲	稳定性提高的(z)‑2‑氰基‑3‑羟基‑丁‑2‑烯酸‑(4’‑三氟甲基苯基)‑酰胺片剂制剂
CN103977594B (zh) *	2014-06-03	2016-02-17	江苏九九久科技股份有限公司	一种结晶方法
US9895370B2 (en) *	2015-11-19	2018-02-20	Pharmedix.Co., Ltd	Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) *	2018-09-03	2019-01-11	深圳市新阳唯康科技有限公司	一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) *	2021-02-04	2022-11-08	美罗药业股份有限公司	一种来氟米特晶型i的制备方法
CN114716388B (zh) *	2021-11-04	2024-02-13	江苏冠军科技集团股份有限公司	一种磺胺-银化合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2524959C2 (de) *	1975-06-05	1983-02-10	Hoechst Ag, 6000 Frankfurt	5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
NL186239B (nl) *	1975-06-05		Hoechst Ag	Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
ES448386A1 (es) *	1975-06-05	1978-04-16	Hoechst Ag	Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2525959A1 (de) *	1975-06-11	1977-02-10	Focke Pfuhl Verpack Automat	Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) *	1978-12-16	1980-07-03	Hoechst Ag	Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) *	1980-10-01	1985-10-31	Glaxo Group Ltd	Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) *	1988-01-26	1990-06-19	Bristol-Myers Company	Antiarthritic isoxazole-4-carboxamides
US5583150A (en) *	1989-08-18	1996-12-10	Alcon Laboratories, Inc.	5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
DK0527736T3 (da) *	1990-05-18	1997-10-20	Hoechst Ag	Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler.
DE4127737A1 (de) *	1991-08-22	1993-02-25	Hoechst Ag	Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) *	1992-04-30	1992-06-17	Roussel Lab Ltd	Chemical compounds
ES2124800T3 (es) *	1993-01-08	1999-02-16	Hoechst Ag	Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
ATE174219T1 (de) *	1993-01-08	1998-12-15	Hoechst Ag	Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
ATE174220T1 (de) *	1993-01-08	1998-12-15	Hoechst Ag	Verwendung von leflunomid zur hemmung von interleukin 8
TW314467B (zh) *	1993-03-31	1997-09-01	Hoechst Ag
GB9320299D0 (en) *	1993-10-01	1993-11-17	Roussel Lab Ltd	Isoxazole derivatives
US5610173A (en) *	1994-01-07	1997-03-11	Sugen, Inc.	Formulations for lipophilic compounds
ATE194912T1 (de) *	1994-10-17	2000-08-15	Aventis Pharma Ltd	Mittel zur vorsorge und heilung von typ i allergischen krankheiten
AR001982A1 (es) *	1995-02-06	1998-01-07	Smithkline Beecham Plc	Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
DE19539638A1 (de) *	1995-10-25	1997-04-30	Hoechst Ag	Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) *	1997-05-19	2001-11-13	Sugen, Inc.	Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) *	1997-06-16	1999-04-30	Lin-Hua Zhang	Crystalline roxifiban
EP0903345B1 (de) *	1997-08-08	2000-10-04	Aventis Pharma Deutschland GmbH	Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6096770A (en) *	1998-08-03	2000-08-01	American Home Products Corporation	Anthranilic acid analogs
DE19908527C2 (de) *	1999-02-26	2001-08-30	Aventis Pharma Gmbh	Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
AU779931B2 (en) *	1999-12-16	2005-02-17	Teva Pharmaceutical Industries Ltd.	Novel processes for making- and a new crystalline form of- leflunomide
ES2237553T3 (es) *	2000-02-15	2005-08-01	Teva Pharmaceutical Industries Ltd.	Procedimiento para la sintesis de leflunomida.
US6727272B1 (en) *	2002-07-15	2004-04-27	Unitech Pharmaceuticals, Inc.	Leflunomide analogs for treating rheumatoid arthritis

1998
- 1998-07-31 EP EP98114373A patent/EP0903345B1/de not_active Expired - Lifetime
- 1998-07-31 AT AT99117098T patent/ATE207065T1/de active
- 1998-07-31 PT PT98114373T patent/PT903345E/pt unknown
- 1998-07-31 ES ES99117098T patent/ES2166205T3/es not_active Expired - Lifetime
- 1998-07-31 DK DK98114373T patent/DK0903345T3/da active
- 1998-07-31 DE DE59801792T patent/DE59801792D1/de not_active Expired - Lifetime
- 1998-07-31 PT PT99117098T patent/PT987256E/pt unknown
- 1998-07-31 ES ES98114373T patent/ES2150808T3/es not_active Expired - Lifetime
- 1998-07-31 EP EP99117098A patent/EP0987256B1/de not_active Expired - Lifetime
- 1998-07-31 DE DE59800287T patent/DE59800287D1/de not_active Expired - Lifetime
- 1998-07-31 AT AT98114373T patent/ATE196764T1/de active
- 1998-07-31 DK DK99117098T patent/DK0987256T3/da active
- 1998-08-05 CZ CZ19982468A patent/CZ292943B6/cs not_active IP Right Cessation
- 1998-08-05 IL IL12567198A patent/IL125671A/en not_active IP Right Cessation
- 1998-08-05 CZ CZ20032982A patent/CZ301514B6/cs not_active IP Right Cessation
- 1998-08-05 CZ CZ20032983A patent/CZ301426B6/cs not_active IP Right Cessation
- 1998-08-06 UA UA98084307A patent/UA54411C2/uk unknown
- 1998-08-06 TW TW087112927A patent/TW593288B/zh not_active IP Right Cessation
- 1998-08-06 US US09/129,783 patent/US6060494A/en not_active Expired - Lifetime
- 1998-08-06 AR ARP980103900A patent/AR015418A1/es active IP Right Grant
- 1998-08-06 NZ NZ331270A patent/NZ331270A/xx not_active IP Right Cessation
- 1998-08-06 TR TR2006/00582A patent/TR200600582A1/xx unknown
- 1998-08-06 SK SK1521-2001A patent/SK285216B6/sk not_active IP Right Cessation
- 1998-08-06 SK SK1058-98A patent/SK282641B6/sk not_active IP Right Cessation
- 1998-08-06 TR TR1998/01513A patent/TR199801513A3/tr unknown
- 1998-08-06 ID IDP981098A patent/ID20667A/id unknown
- 1998-08-07 JP JP10224015A patent/JPH11124372A/ja active Pending
- 1998-08-07 HU HU0700190A patent/HU229232B1/hu unknown
- 1998-08-07 CA CA002245267A patent/CA2245267C/en not_active Expired - Lifetime
- 1998-08-07 AU AU78870/98A patent/AU752764B2/en not_active Expired
- 1998-08-07 BR BR9806568-8A patent/BR9806568A/pt not_active Application Discontinuation
- 1998-08-07 CN CN98116235A patent/CN1089759C/zh not_active Expired - Lifetime
- 1998-08-07 KR KR1019980032110A patent/KR100544041B1/ko not_active IP Right Cessation
- 1998-08-07 HU HU9801844A patent/HU225870B1/hu unknown
- 1998-08-07 RU RU98115390/04A patent/RU2224753C2/ru active
- 1998-08-07 CN CNB021045747A patent/CN1181064C/zh not_active Expired - Lifetime
- 1998-08-07 NO NO19983632A patent/NO310871B1/no not_active IP Right Cessation
- 1998-08-07 PL PL327901A patent/PL192126B1/pl unknown
1999
- 1999-06-30 HK HK99102767A patent/HK1017681A1/xx not_active IP Right Cessation
- 1999-10-28 US US09/428,499 patent/US6221891B1/en not_active Expired - Lifetime
2000
- 2000-11-10 GR GR20000402501T patent/GR3034814T3/el unknown
2001
- 2001-01-19 US US09/764,258 patent/US6552202B2/en not_active Expired - Lifetime
2002
- 2002-11-25 US US10/302,872 patent/US6900334B2/en not_active Expired - Lifetime
2003
- 2003-02-19 HK HK03101247.6A patent/HK1049481B/zh not_active IP Right Cessation
2004
- 2004-04-23 US US10/830,307 patent/US6995272B2/en not_active Expired - Lifetime
2005
- 2005-06-28 KR KR1020050056044A patent/KR100588254B1/ko not_active IP Right Cessation
2009
- 2009-07-28 JP JP2009175137A patent/JP2009280604A/ja active Pending

Also Published As

Publication number	Publication date
UA54411C2 (uk)	2003-03-17
SK105898A3 (en)	1999-02-11
HUP9801844A2 (hu)	2000-02-28
HU225870B1 (en)	2007-11-28
CA2245267C (en)	2008-12-23
TW593288B (en)	2004-06-21
CZ301514B6 (cs)	2010-03-31
DE59801792D1 (de)	2001-11-22
PL327901A1 (en)	1999-02-15
HU229232B1 (en)	2013-09-30
US6552202B2 (en)	2003-04-22
CN1373126A (zh)	2002-10-09
JP2009280604A (ja)	2009-12-03
TR199801513A2 (xx)	1999-02-22
US6221891B1 (en)	2001-04-24
JPH11124372A (ja)	1999-05-11
US6060494A (en)	2000-05-09
CN1089759C (zh)	2002-08-28
TR199801513A3 (tr)	1999-02-22
US6900334B2 (en)	2005-05-31
CZ301426B6 (cs)	2010-02-24
IL125671A (en)	2002-11-10
US20030166945A1 (en)	2003-09-04
KR100588254B1 (ko)	2006-06-12
CN1208034A (zh)	1999-02-17
CA2245267A1 (en)	1999-02-08
ES2166205T3 (es)	2002-04-01
US20030027851A1 (en)	2003-02-06
CN1181064C (zh)	2004-12-22
ID20667A (id)	1999-02-11
EP0987256A1 (de)	2000-03-22
DE59800287D1 (de)	2000-11-09
CZ292943B6 (cs)	2004-01-14
HK1017681A1 (en)	1999-11-26
IL125671A0 (en)	1999-04-11
AU7887098A (en)	1999-02-18
PT987256E (pt)	2002-03-28
ATE196764T1 (de)	2000-10-15
DK0903345T3 (da)	2000-10-23
PL192126B1 (pl)	2006-09-29
BR9806568A (pt)	2000-05-16
NO983632D0 (no)	1998-08-07
US6995272B2 (en)	2006-02-07
RU2224753C2 (ru)	2004-02-27
KR20050077498A (ko)	2005-08-02
HU9801844D0 (en)	1998-10-28
CZ246898A3 (cs)	1999-02-17
AU752764B2 (en)	2002-09-26
NO983632L (no)	1999-02-09
SK285216B6 (sk)	2006-09-07
TR200600582A1 (tr)	2006-08-21
ES2150808T3 (es)	2000-12-01
EP0903345A1 (de)	1999-03-24
DK0987256T3 (da)	2002-02-11
AR015418A1 (es)	2001-05-02
NO310871B1 (no)	2001-09-10
EP0903345B1 (de)	2000-10-04
PT903345E (pt)	2001-01-31
HU0700190D0 (en)	2007-05-02
HK1049481A1 (en)	2003-05-16
GR3034814T3 (en)	2001-02-28
HUP9801844A3 (en)	2000-04-28
KR100544041B1 (ko)	2006-09-18
EP0987256B1 (de)	2001-10-17
ATE207065T1 (de)	2001-11-15
NZ331270A (en)	2000-04-28
US20040204465A1 (en)	2004-10-14
KR19990023433A (ko)	1999-03-25
SK282641B6 (sk)	2002-10-08

Publication	Publication Date	Title
HK1049481B (zh)	2005-07-08	結晶形式的n-(4-三氟甲基苯基)-5-甲基異噁唑-4-甲酰胺的製備方法
ZA986362B (en)	1999-01-22	Crystal modification of a N-phenyl-2-pyrimidine amine derivative processes for its manufacture and its use
HUP0004388A3 (en)	2001-10-29	Process for the preparation of oxazolidinones, intermediates and preparation thereof
KR960704095A (ko)	1996-08-31	화합물 단결정의 제조방법 및 제조장치(method and apparatus for preparing compound single crystals)
AR017655A1 (es)	2001-09-12	Metodo para preparar eteres de monofluormetilo
EP1035234A4 (en)	2003-05-28	HIGH QUALITY SINGLE SILICON CRYSTAL AND MANUFACTURING METHOD
PL323923A1 (en)	1998-04-27	Method of making cement clinker
HK1022695A1 (en)	2000-08-18	Method for debenzylation of dibenzylbiotin
ZA986320B (en)	1999-02-02	A method for the preparation of tertiary amines a compound useful therefor and alpha-2-receptor active tetrahyd-roisoquinoline derivatives
EP0724028A3 (en)	1997-04-16	Process for producing wire-like silicon a crystal
FI970244A0 (fi)	1997-01-21	Menetelmä vakiinnuttaa toonisen munasarjaestrogeenin erittyminen jatkettuja hoitotapoja varten
NO932696D0 (no)	1993-07-27	Fremgangsmaate for fremstilling av hvit microsilica
AP2000001732A0 (en)	2000-03-31	Method for preparing alkyloxy furnanone derivatives compounds obtained by said method and use of said method and use of said compounds
IL144867A0 (en)	2002-06-30	Method of crystallising n-(4-trifluoromethylphenyl)-5-methyl-isoxazole-4-carboxamide
ZA984534B (en)	1998-12-07	Method for the preparation of carbamates
HUP9600097A3 (en)	1997-08-28	Process for preparation of 5-substituted 2-chloropyridines
IL139438A0 (en)	2001-11-25	Crystal form of n- (4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
FI952104A0 (fi)	1995-05-03	Menetelmä epäorgaanisten yhdisteiden jauheiden valmistamiseksi
ZA987127B (en)	1999-02-08	Crystal form of N-(4-trifuloromethylphenyl)-5-methylisoxazole-4-carboxamide
SI0987256T1 (en)	2002-04-30	Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamid
AP2000001781A0 (en)	2000-06-30	Process for preparation of azacycloalkylalkanoyl pseudotetrapeptides
ZA9811238B (en)	1999-06-22	Process for the preparation of isopropyl-methyl-(2-(3-n-propoxyphenoxy)ethyl)amine
EG21226A (en)	2001-03-31	Process for preparing of new pharmaceutical compound
ZA9810718B (en)	1999-05-25	Novel crystal modification of thiazine-indigo
HK1016156A1 (en)	1999-10-29	Method of preparing 2-trifluoromethoxybenzene sulphonamide

Legal Events

Date	Code	Title	Description
2018-08-24	PE	Patent expired	Effective date: 20180806